In this episode, Alan Brown, MD, FACC, MNLA sits down with Rebecca Juliano, PhD, MPhil, MA to discuss a first-in-human study of an investigational ANGPTL4 inhibitory antibody. The conversation explores how this novel therapeutic approach safely and effectively reduces plasma triglycerides and remnant cholesterol—key drivers of residual cardiovascular risk. Listeners will gain insight into the mechanism of action, clinical significance, and potential role of ANGPTL4 inhibition in the evolving landscape of lipid management.
Podcasts
